Anjana Rao

This inventor holds 34 USPTO granted patents and 31 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Epigenetic Modifications. Top assignees: Children's Medical Center Corporation, The United States of America, as Represented by the Secretary, Department of Health and Human Services, Immune Disease Institute, Inc.. Active years: 1997-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anjana Rao. Retrieved from https://idiyas.com/inventor/anjana-rao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 34 (Patent Applications = 31)

% Patents Active = 85.3

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 4.4

ph-index = 13

Forward Citations = 361(Granted Patents)

Location History:

Cambridge, MA (US) (1997 - 2018)
La Jolla, CA (US) (2016 - 2024)

Company Filing History:

25 out of 1,072

Children's Medical Center Corporation

patents

21 out of 3,693

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

4 out of 12

Immune Disease Institute, Inc.

Dana-Farber-Cancer Institute Inc.

patents

7. 1 out of 10

The Cbr Institute for Biomedical Research, Inc.

patents

8. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2025

Loading Chart...

Areas of Expertise:

5-Methylcytosine

Epigenetic Analysis

TET-Family Proteins

Hydroxymethylcytosine

NFAT Regulators

Glycosylation

Cancer Detection

tRNA Synthetases

Immune-Related Diseases

Specific Inhibitors

Gene Regulation

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12467082 - SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS (2025-11-11),

2. 12338489 - Selective oxidation of 5-methylcytosine by TET-family proteins (2025-06-24),

3. 12331346 - Selective oxidation of 5-methylcytosine by TET-family proteins (2025-06-17),

4. 12291742 - Selective oxidation of 5-methylcytosine by TET-family proteins (2025-05-06),

5. 12018320 - Selective oxidation of 5-methylcytosine by TET-family proteins (2024-06-25),

6. 11208683 - Methods of epigenetic analysis (2021-12-28),

7. 11072818 - Selective oxidation of 5-methylcytosine by TET-family proteins (2021-07-27),

8. 10793899 - Methods for identifying hydroxylated bases (2020-10-06),

9. 10774373 - Compositions comprising glucosylated hydroxymethylated bases (2020-09-15),

10. 10767216 - Methods for distinguishing 5-hydroxymethylcytosine from 5-methylcytosine (2020-09-08),

11. 10731204 - Selective oxidation of 5-methylcytosine by TET-family proteins (2020-08-04),

12. 10612076 - Selective oxidation of 5-methylcytosine by TET-family proteins (2020-04-07),

13. 10533213 - Selective oxidation of 5-methylcytosine by TET-family proteins (2020-01-14),

14. 10508301 - Detection of 5-hydroxymethylcytosine by glycosylation (2019-12-17),

15. 10465234 - Selective oxidation of 5-methylcytosine by TET-family proteins (2019-11-05),

Title: The Innovative Mind of Anjana Rao

Introduction: Anjana Rao, a pioneering inventor based in La Jolla, CA, is renowned for her groundbreaking contributions to the field of biotechnology and genetics.

Latest Patents: Anjana Rao holds several patents related to gene editing technologies and novel therapeutic approaches for genetic disorders, with her most recent patent focusing on a revolutionary method for targeted gene therapy.

Career Highlights: With a distinguished career spanning over three decades, Anjana Rao has held key research positions at prestigious institutions such as the Salk Institute for Biological Studies and the University of California, San Diego. Her research has led to significant advancements in understanding gene regulation and its implications for human health.

Collaborations: Anjana Rao has collaborated with leading scientists and biotech companies worldwide to further the development and application of her innovative technologies. Her collaborative efforts have resulted in the successful translation of her research findings into tangible solutions for genetic diseases.

Conclusion: Anjana Rao's relentless pursuit of scientific excellence and her commitment to innovation have solidified her reputation as a trailblazer in the field of biotechnology. Her work continues to inspire future generations of inventors and researchers to push the boundaries of what is possible in the realm of genetic engineering and therapeutics.

Profile summary based on public USPTO records.